Breast Cancer Trial Results
Study Confirms Letrozole Prevents More Breast Cancer Recurrences than Tamoxifen
(Posted: 12/02/2011) - After a median of 8 years of follow-up from a large randomized trial, women with estrogen-receptor positive breast cancer who received 5 years of treatment with letrozole were less likely to have their cancer recur or to die during follow-up than women who had 5 years of treatment with tamoxifen.
Radiation Therapy after Breast-Conserving Surgery Improves Survival
(Posted: 12/02/2011) - Radiation therapy after breast-conserving surgery substantially reduces the risk of cancer recurring in the breast and moderately reduces the risk of death from the disease, according to updated results from a meta-analysis by the Early Breast Cancer Trialists' Collaborative Group.
Long-Term Data from 20 Trials Confirm Tamoxifen’s Long-Lasting Benefit
(Posted: 11/23/2011) - In an analysis of data from participants in 20 clinical trials, women with estrogen receptor-positive breast cancer who received about 5 years of adjuvant treatment with tamoxifen had a lower risk of recurrence in the 15 years after starting treatment than women who did not receive tamoxifen.
Chemotherapy Less Toxic to the Heart May Be Option for Some Women with HER2-Positive Breast Cancer
(Posted: 11/03/2011) - A nonanthracycline-containing chemotherapy regimen combined with the targeted therapy trastuzumab may be an option for some women with HER2-positive breast cancer, according to results from the Breast Cancer International Research Group 006 (BCIRG-006) trial reported October 6, 2011, in the New England Journal of Medicine.
Zoledronic Acid Did Not Improve Disease-Free Survival in Breast Cancer
(Posted: 12/27/2010, Updated: 10/20/2011) - The addition of zoledronic acid to standard adjuvant therapy did not extend disease-free survival for women with stage II or III breast cancer in the phase III AZURE trial, results of which were presented at the 2010 San Antonio Breast Cancer Symposium.
(Posted: 12/02/2011) - After a median of 8 years of follow-up from a large randomized trial, women with estrogen-receptor positive breast cancer who received 5 years of treatment with letrozole were less likely to have their cancer recur or to die during follow-up than women who had 5 years of treatment with tamoxifen.
Radiation Therapy after Breast-Conserving Surgery Improves Survival
(Posted: 12/02/2011) - Radiation therapy after breast-conserving surgery substantially reduces the risk of cancer recurring in the breast and moderately reduces the risk of death from the disease, according to updated results from a meta-analysis by the Early Breast Cancer Trialists' Collaborative Group.
Long-Term Data from 20 Trials Confirm Tamoxifen’s Long-Lasting Benefit
(Posted: 11/23/2011) - In an analysis of data from participants in 20 clinical trials, women with estrogen receptor-positive breast cancer who received about 5 years of adjuvant treatment with tamoxifen had a lower risk of recurrence in the 15 years after starting treatment than women who did not receive tamoxifen.
Chemotherapy Less Toxic to the Heart May Be Option for Some Women with HER2-Positive Breast Cancer
(Posted: 11/03/2011) - A nonanthracycline-containing chemotherapy regimen combined with the targeted therapy trastuzumab may be an option for some women with HER2-positive breast cancer, according to results from the Breast Cancer International Research Group 006 (BCIRG-006) trial reported October 6, 2011, in the New England Journal of Medicine.
Zoledronic Acid Did Not Improve Disease-Free Survival in Breast Cancer
(Posted: 12/27/2010, Updated: 10/20/2011) - The addition of zoledronic acid to standard adjuvant therapy did not extend disease-free survival for women with stage II or III breast cancer in the phase III AZURE trial, results of which were presented at the 2010 San Antonio Breast Cancer Symposium.
